Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * BIENAIME JEAN JACQUES	2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [ BMRN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Executive Officer
(Last)          (First)          (Middle) C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.	3. Date of Earliest Transaction (MM/DD/YYYY) 4/27/2020
(Street) SAN RAFAEL, CA 94901 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	4/27/2020 (1)		M		20000	A	$21.51	318213	D
Common Stock	4/27/2020 (1)(2)(3)		S		20000	D	$97.73	298213	D
Common Stock	4/28/2020 (1)		M		20000	A	$21.51	318213	D
Common Stock	4/28/2020 (1)		S		20000	D	$97.58	298213	D
Common Stock								247958	I	Shares held by Jean-Jacques Bienaime Family Trust

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy Common Stock)	$21.51	4/27/2020 (1)		M			20000	11/12/2010	5/11/2020	Common Stock	20000	$0	49000 (4)	D
Stock Option (Right to buy Common Stock)	$21.51	4/28/2020 (1)		M			20000	11/12/2010	5/11/2020	Common Stock	20000	$0	29000 (4)	D

Explanation of Responses:
(1)	Trade made pursuant to a 10b5-1 plan executed on November 13, 2019.
(2)	The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 10 shares, with the reporting person's purchase of shares at a price of $75.3786 on November 11, 2019. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
(3)	The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 30 shares, with the reporting person's purchase of shares at a price of $94.39 on March 3, 2020. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
(4)	Reflects the number of options outstanding after the transactions from this specific stock option grant.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901	X		Chief Executive Officer

Signatures
/s/ Eric Fleekop, Attorney-in-Fact		4/29/2020
**Signature of Reporting Person		Date